Nitrofurantoin,
does it really help with Symptom resolution and clinical cure of acute uncomplicated cystitis in women?
research showsNitrofurantoin is rated B because symptom resolution and clinical cure of acute uncomplicated cystitis in women were replicated in multiple active-control randomized trials. Gupta 2007 randomized 338 women and analyzed 308 with follow-up; 30-day clinical cure was 84% versus 79%, meeting the primary equivalence endpoint against trimethoprim-sulfamethoxazole. Huttner 2018 randomized 513 women and had primary-endpoint data for 485; 28-day clinical resolution was 70% versus 58%, a 12-point difference (95% CI 4 to 21, P=.004), superior to fosfomycin. Both used active controls rather than placebo.
ads claimDescriptions can broaden the drug into a treatment for every urinary infection. This verdict covers lower acute uncomplicated cystitis in nonpregnant women, not pyelonephritis or complicated infection.
Useful facts when choosing a product
- The tested regimen was 100 mg twice daily for five days in Gupta and 100 mg three times daily for five days in Huttner. Actual prescribing varies by country, formulation, and kidney function.
- Fever or flank pain suggesting upper infection, pregnancy, and reduced kidney function require separate clinical assessment and drug selection.
What the research actually shows
Gupta and colleagues openly randomized 338 women and analyzed 308 with follow-up, 160 on nitrofurantoin and 148 on trimethoprim-sulfamethoxazole. Thirty-day clinical cure was 84% versus 79%, meeting the prespecified plus-or-minus 10% equivalence criterion. Huttner and colleagues randomized 513 women; primary 28-day outcome data were available for 485, 244 versus 241. Clinical resolution occurred in 171/244 (70%) versus 139/241 (58%), difference 12 points (95% CI 4 to 21), P=.004, so the primary endpoint succeeded. Verdict 1795 is C with 56 points for methenamine prevention of recurrence, a different purpose from this acute treatment.
Why this is classified as B (68)
Direct symptom cure replicated across randomized trials, and the 12-point Huttner difference exceeded the stated 10-point threshold. Both trials were open-label and used only active controls without placebo, so B1 yields B with 68 points.
Counterpoint. Culture results, resistance, kidney function, pregnancy potential, and signs of upper infection can make another antibiotic more appropriate. Drug selection requires individual care.
Rejudgment record. Cross-check applied — Independent active-control replication of direct clinical cure with a prespecified MCID exceeded
| Endpoint | P | Patient-reported treatment goal - the symptom is the goal |
| Replication | R2 | Independently replicated across trials |
| Independence | I1 | Mixed funding sources |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (B).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Clinical cure at 30 days | B | The prespecified equivalence criterion versus trimethoprim-sulfamethoxazole was met. |
| Complete symptom resolution through day 28 | B | Resolution was 12 points higher than fosfomycin and exceeded the prespecified MCID. |
| Early clinical cure | B | It was equivalent to active control, and the later trial also favored treatment at day 14. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Gupta K et al. 2007 | Open-label randomized active-control equivalence trial | 1 | Mixed partial support from Procter & Gamble and public US Public Health Service grants DK 53369 and DK 02660; sponsors had no trial or analysis role | Primary clinical cure outcome 30 days after therapy | Cure was 84% versus 79%, a 5-point difference meeting the prespecified plus-or-minus 10% equivalence criterion; the primary endpoint succeeded. | Active-control equivalence confirmation |
| Huttner A et al. 2018 | Open-label, analyst-blinded, multinational randomized active-control superiority trial | 1 | Public funding from the European Commission FP7 and Polish Ministry of Science and Higher Education | Complete clinical resolution through day 28 | Resolution was 70% versus 58%, difference 12 points (95% CI 4 to 21), P=.004; the primary endpoint succeeded and exceeded the prespecified 10-point MCID. | Independent publicly funded superiority replication |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-24).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Nitrofurantoin x clinical cure of acute uncomplicated cystitis — Evidence Grade B·68. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/womens/nitrofurantoin-acute-uncomplicated-cystitis-clinical-cure/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.